Targeting molecular resistance in castration-resistant prostate cancer

Multiple mechanisms of resistance contribute to the inevitable progression of hormone-sensitive prostate cancer to castration-resistant prostate cancer (CRPC). Currently approved therapies for CRPC include systemic chemotherapy (docetaxel and cabazitaxel) and agents targeting the resistance pathways...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandrasekar, Thenappan, Yang, Joy C., Gao, Allen C., Evans, Christopher P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556222/
https://www.ncbi.nlm.nih.gov/pubmed/26329698
http://dx.doi.org/10.1186/s12916-015-0457-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556222/
https://www.ncbi.nlm.nih.gov/pubmed/26329698
http://dx.doi.org/10.1186/s12916-015-0457-6

Ejemplares similares